Using AI for Mass Screening of Obstructive Sleep Apnea
July 19, 2019
An international research team led by the Technion–Israel Institute of Technology has developed an innovative, AI-based technology for monitoring obstructive sleep apnea (OSA). The prevalence of this syndrome increases with age and affects more than one in five individuals in the general adult population, particularly males and those who are overweight.
OSA is characterized by halts in breathing that last for 10 seconds or more during the night and lower oxygen levels in the blood. The syndrome causes fatigue and sleepiness during the day, which can lead to inefficiency and accidents while working, and in some cases, to road accidents. OSA also increases the risk of developing diabetes and cardiovascular disease.
The study was led by Assistant Professor Joachim Behar, a member of the Technion’s Faculty of Biomedical Engineering,. The findings were published in The Lancet Group’s open-access journal EClinicalMedicine.
“Sleep apnea can be treated effectively, but many sufferers remain undiagnosed,” said Prof. Behar.
The technology used to diagnose the syndrome in sleep labs, called polysomnography, records brain waves and the oxygen level in the blood, as well as the heart rate, breathing and eye and leg movements during sleep.
Although polysomnography is effective in diagnosing the condition, it is not widely available because of its prohibitive costs. OSA diagnosis may also be carried out with home monitoring equipment, though this option is not without cost, nor is it easily accessible to the general population at risk. Less expensive diagnostic methods, based on questionnaires and upper-respiratory morphology, are not accurate enough.
The technology that Prof. Behar and his team developed is based on data from 887 subjects from the general adult population in Sao Paulo, Brazil. The technology received this data and, using artificial intelligence, succeeded in differentiating between OSA sufferers, and those who do not have it.
The diagnosis was made on the basis of integrating biomarkers obtained from the patients that include oxygen saturation (pulse oximetry) during sleep, demographic information (such as age, height, and weight) and anthropometric information such as neck dimension. The system was able to successfully identify all important clinical cases of medium or severe OSA. Standardized sleep apnea diagnosis questionnaires, by comparison, missed more than 15% of severe cases. The use of pulse oximetry only detected all severe cases, but failed to identify some of the medium OSA cases.
“This means that the model we developed is a reliable and effective tool for identifying sleep apnea in large populations,” Prof. Behar said. In the future, with the development of a suitable mobile application, the model will make it possible for anyone with a smart watch or bracelet that includes an oximeter to perform an accurate self-examination for OSA.”
The model the team developed is called OxyDOSA. It is currently available for research at: https://aim-lab.github.io/oxydosa.html.
Professor Joachim Behar received his PhD from the University of Oxford in the UK and master’s degree from l’Ecole des Mines de Saint-Étienne in France. He is the head of the Artificial Intelligence in Medicine Lab (AIMLab) in the Technion Faculty of Biomedical Engineering.
For more than a century, the Technion–Israel Institute of Technology has pioneered in science and technology education and delivered world-changing impact. Proudly a global university, the Technion has long leveraged boundary-crossing collaborations to advance breakthrough research and technologies. Now with a presence in three countries, the Technion will prepare the next generation of global innovators. Technion people, ideas, and inventions make immeasurable contributions to the world, innovating in fields from cancer research and sustainable energy to quantum computing and computer science to do good around the world.
The American Technion Society supports visionary education and world-changing impact through the Technion–Israel Institute of Technology. Based in New York City, we represent thousands of US donors, alumni, and stakeholders who invest in the Technion’s growth and innovation to advance critical research and technologies that serve the State of Israel and the global good. Over more than 75 years, our nationwide supporter network has funded new Technion scholarships, research, labs, and facilities that have helped deliver world-changing contributions and extend Technion education to campuses in three countries.